Clinical pharmacology and pharmacokinetics of levetiracetam

Chanin Wright, Jana Downing, Diana Mungall, Owais Khan, Amanda Williams, Ekokobe Fonkem, Darin Garrett, Jose Aceves, Batool Kirmani

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Status epilepticus and acute repetitive seizures still pose a management challenge despite the recent advances in the field of epilepsy. Parenteral formulations of old anticonvulsants are still a cornerstone in acute seizure management and are approved by the FDA. Intravenous levetiracetam (IV LEV), a second generation anticonvulsant, is approved by the FDA as an adjunctive treatment in patients 16 years or older when oral administration is not available. Data have shown that it has a unique mechanism of action, linear pharmacokinetics and no known drug interactions with other anticonvulsants. In this paper, we will review the current literature about the pharmacology and pharmacokinetics of IV LEV and the safety profile of this new anticonvulsant in acute seizure management of both adults and children.

Original languageEnglish (US)
Article numberArticle 192
JournalFrontiers in Neurology
Volume4 DEC
DOIs
StatePublished - Dec 1 2013

    Fingerprint

Keywords

  • Epilepsy
  • Levetiracetam
  • Pharmacokinetics

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Wright, C., Downing, J., Mungall, D., Khan, O., Williams, A., Fonkem, E., Garrett, D., Aceves, J., & Kirmani, B. (2013). Clinical pharmacology and pharmacokinetics of levetiracetam. Frontiers in Neurology, 4 DEC, [Article 192]. https://doi.org/10.3389/fneur.2013.00192